FT : SoftBank jumps into e-scooters with $250m Tier Mobility deal

SoftBank jumps into e-scooters with $250m Tier Mobility deal
Latest investment values Berlin-based electric scooter start-up just below $1bn

SoftBank’s Vision Fund has made its first investment into the fast-growing but volatile electric scooter-sharing market, backing Berlin-based Tier Mobility in the largest funding round for a European e-scooter company to date.

Tier on Tuesday said SoftBank’s second Vision Fund had led a $250m investment in the company, which has pioneered a novel model of swappable batteries and local charging networks that investors say has enabled it to operate profitably, even when usage was hit by lockdowns.

The investment valued the start-up just below $1bn, including the new funds raised, said people briefed on the terms, allowing it to overtake Lime to become the second-most valuable e-scooter company after Bird.

Lawrence Leuschner, Tier’s chief executive and co-founder, said the company has been profitable, excluding interest and tax payments, since the summer.

Mr Leuschner said that as a result, Tier has been able to use debt financing to pay for new e-scooters, instead of burning through venture capital. The new equity from SoftBank and others will be used to expand into new kinds of so-called “micromobility” vehicles, which are smaller and less polluting than traditional cars, and build out its charging network.

“If we all switch from diesel cars to electric cars, we are going to save CO2 and other emissions but we are not solving the problem of congestion and parking,” he said. “The vision here is to build an energy network and different [vehicle] solutions in one app, so that you can leave your car at home.”

Scooters with swappable batteries can be topped up more easily and cheaply, because the vehicles do not have to be pulled off the streets and shuttled to warehouses for recharging. Tier also has a growing network of automated charging stations inside cafés and retailers.

Investors have ploughed hundreds of millions of dollars into e-scooters since 2017, when Bird first pioneered the model of on-street rentals that can be picked up and dropped off anywhere via a smartphone app.

But many of those funds were spent on buying vehicles that lasted only a few months before being stolen, vandalised or scrapped — and that was before the coronavirus pandemic forced several operators to suspend operations in many cities.

Bird laid off hundreds of employees in March and Lime’s valuation was cut from more than $2bn to about $500m in May, when Uber led a $170m investment.

Paul Murphy, general partner at Northzone Ventures, said later-stage investors who had “previously been on the sidelines” of e-scooter investing got more interested when they saw how Tier’s charging network changed the economics of the business.

Tier’s existing investors, including Abu Dhabi’s Mubadala investment arm, Goodwater Capital, Northzone, and White Star Capital, also participated in the funding round.

“Tier’s response during the pandemic showed how much better its operating model was than every other micromobility operator,” Mr Murphy said. “This is Mubadala and SoftBank stepping in to say, ‘This is the winner’.”

As commuters seek Covid-friendly alternatives to trains and buses, scooter operators believe they have a new opportunity to prove that they are not simply a Segway-style fad. The UK accelerated its plans to legalise rented e-scooters this summer, in response to the pandemic.

Tier operates in more than 80 cities in 10 countries across Europe and the Middle East. After winning an operating licence in Paris earlier this year, Mr Leuschner said he was “evaluating” applying for a permit in New York City, which plans to allow scooters for the first time next year.

SoftBank’s investment is the first European deal from its second Vision Fund, which is backed by the company’s balance sheet rather than outside investors.

The Japanese company backed Tier after determining Europe is a more attractive market for e-scooters than the US and Asia, one person familiar with its thinking said.

The Vision Fund recovered slightly in the third quarter after suffering from a series of underwater bets on start-ups such as the property group WeWork, reporting gains from mark ups and exited investments.

>>> Europe : Brokers Upgrades & Downgrades - 10th of November 2020

>>> Up
* Banco Santander Raised to Outperform at KBW; PT 2.90 euros
* Barclays Raised to Add at AlphaValue
* CGG Raised to Buy at SocGen; PT 67 euro cents
* DSM PT Raised to 180 euros from 160 euros at Deutsche Bank
* Enel Raised to Buy at LBBW; PT 8.60 euros
* Greggs Raised to Overweight at Barclays; PT 1,890 pence
* GVC PT Raised to 1,600 pence from 1,200 pence at Peel Hunt
* ICADE Raised to Neutral at Goldman; PT 50.50 euros
* Infineon Raised to Buy at LBBW; PT 29.50 euros
* Jumbo Raised to Buy at HSBC; PT 18.50 euros
* LafargeHolcim Raised to Outperform at Exane; PT 52 Swiss francs
* Lancashire Raised to Buy at HSBC; PT 780 pence
* Mitie Raised to Buy at Liberum; PT 40 pence
* Next Raised to Buy at Goldman; PT 7,600 pence
* Opap Raised to Buy at HSBC; PT 10.50 euros
* Orsted AS Raised to Overweight at Morgan Stanley
* Richter Raised to Buy at HSBC; PT 8,200 forint
* UniCredit Raised to Buy at AlphaValue

>>> Down
* Flutter Cut to Reduce at Peel Hunt; PT 12,600 penceNext Raised to Buy at Goldman; PT 7,600 pence
* On The Beach Cut to Neutral at Citi; PT 370 pence
* RSA Cut to Neutral at Citi; PT 685 pence
* Scandinavian Tobacco Cut to Equal-Weight at Barclays
* Solvay Cut to Add at AlphaValue
* Taylor Wimpey Cut to Hold at Deutsche Bank; PT 147 pence
* Verbund Cut to Sell at SocGen; PT 45.20 euros

>>> Initiation
* Alfa Laval Resumed Equal-Weight at Morgan Stanley
* Allegro Rated New Hold at Wood & Company; PT 93 zloty
* Beazley Rated New Overweight at Barclays; PT 391 pence
* Lonza Rated New Sector Weight at KeyBanc
* Permanent TSB Reinstated Hold at Deutsche Bank
* Prosegur Reinstated Buy at HSBC; PT 2.90 euros
* Prosegur Cash Reinstated Buy at HSBC; PT 1.10 euros
* Sartorius Rated New Sector Weight at KeyBanc
* Spie Reinstated Hold at HSBC; PT 15 euros

>>> Call
* Covid Vaccine Progress Improves Catering Outlook; Citi Lifts PTs
* Alfa Laval Valuation Attractive But Lacks Near-Term Catalyst: MS
* Ericsson’s Unchanged 2022 Target May Weigh on Sentiment: Citi
* REFINER RALLY `OVERDONE' ON VACCINE NEWS, TUDOR PICKERING SAYS
* Big Oil’s Energy Transition Threat to Utilities Overdone: MS
* Flutter Now Overvalued, GVC and 888 Undervalued, Peel Hunt Says

>>> What to look at today - 10th of November 2020

A rally in global stocks stalled in Asian trading Tuesday amid concerns a large-scale coronavirus vaccine study still has hurdles to clear despite promising results. Bonds and other haven assets climbed after overnight declines.
Shares pared gains in Japan, Hong Kong and Australia, and Chinese stocks fell. S&P 500 futures and European contracts declined. Concerns about a smaller U.S. fiscal stimulus package, still surging coronavirus cases and legal challenges to the U.S. election outcome weighed on the positive vaccine sentiment.
Earlier, the S&P 500 closed at a two-month high on news the coronavirus shot being developed by Pfizer Inc. and BioNTech SE prevented over 90% of infections. The Nasdaq 100 fell as investors rotated out of defensive technology names into shares depressed by the economic impact of lockdowns.
Yields on 10-year Treasuries traded around their highest since March. A measure of credit-market risk eased to pre-pandemic levels, and U.S. junk-bond yields fell to a record low. The dollar slipped. Oil pulled back after surging. Gold and the Japanese yen pared some of Monday’s losses.
US After Hours BYND -22.1%, NBIX -13.4%, RAMP -11.4% down on earnings; XPER +25.7% jumps as it settles litigation with Comcast; ARNA -18% falls on clinical data

Nikkei +0.26% Hang Seng +0.30% CSI -0.78% Shanghai -0.57% Shenzen -1.34%

Eur$ 1.1827 CNH 6.6095 CNY 6.6185 JPY 105.01 GBP 1.3179 CHF 0.9135 RUB 76.59 TRY 8.3737 WTI$39.69 -1.51%

S&P -0.20% Nasdaq -0.20% EuroStoxx -0.96% FTSE -1.15% Dax -1.15% SMI +1.1%

Macro :
- Brazil Halts China Vaccine Trial After Serious Adverse Event
- Sinovac Says Confident on Vaccine Safety After Brazil Trial Halt
- CITI SAYS SELL FINANCIAL STOCKS INTO RALLY; BANKS SURGE 13%
- U.S. Posts Record Cases; Vaccine Study Spurs Hope: Virus Update
- China Turns Up Heat on Internet Giants With Antitrust Rules

Keep an eye on :
- ACOMO NA : SunOpta Agrees to Sell Global Ingredients Segment to Acomo
- ADP FP : ADP Says Airports Have Around 10% of Pre-Pandemic Traffic Now
- ADS GY : Adidas 3Q Net Profit, Sales Fell But Beat Estimates
- ADS GY : Adidas Replaces Govt-Backed Facility With EU1.5b Syndicated Loan
- AF FP : France Could Increase Air France Aid If Needed, Le Maire Says
- AKER NO : Norway Seeks Authority to Sell Aker Solutions, Akastor Stakes
- ARBN SW : Arbonia Issues CHF250M Syndicated Loan; Refinances Existing Loan
- BAKKA NO : Bakkafrost 3Q Operating Ebit Misses Estimates
- BAYN GY : Bayer-Roundup Judge Moves to Resume Cancer Trials in U.S. (1)
- BB FP : BIC Signs Agreement to Sell Clichy HQ and Sites for EU175M, BIC Sees EU50M Annual Savings by ‘22; Div Pay-Out Ratio 40%-50%
- CARLB DC : Carlsberg Fires Employees After Rules Breaches Found: Berlingske
- CNHI IM : Nikola 3Q Adjusted Loss Per Share 16c, Est. Loss/Share 20c
- CNHI IM : Electric-Truck Startup Nikola Says Talks With GM Ongoing (3)
- CON SW : Recticel Buys Conzzeta’s FoamPartner in Cash Deal; EV CHF270m
- CSGN SW : Mozambique Charges ex-Minister Chang Over $2 Billion Scandal (1)
- DPW GY : Deutsche Post 3Q Revenue Meets Estimates
- DEZ GY : Deutz 3Q Adjusted Ebit Loss EU15.7M, Est. EU17.0M
- DSM LN : DSM NV: Good Q3s (robust Nutrition, Materials improvement). Outlook unchanged
- ZIL2 GY : ElringKlinger 3Q Sales Miss Estimates
- ENG SS : Swedbank Robur Accepts Raised Offer for IES
- ERICB SS : Ericsson’s Unchanged 2022 Target May Weigh on Sentiment: Citi
- HAB GY : Hamborner REIT Maintains FY FFO EU52M to EU54M
- HLE GY : Hella 1.17m Shares Are Said Offered via Bankhaus Lampe KG
- HEN3 GY ; Henkel 3Q Revenue Beats Estimates
- HBH GY : Hornbach Holding Boosts FY Adjusted Ebit Forecast
- ITP FP : Inter Parfums 3Q EPS Beats Estimates
- JEN GY : Jenoptik 9M Ebit EU32.7M
- LDO IM : Italy’s Leonardo Is Said to Consider IPO of Its U.S. Unit DRS
- MUX GY : Saint-Gobain in Exclusive Talks With Mutares to Sell Lapeyre
- NENTB SS : Nent Weighs SEK3.5b Equity Raise to Fund International Expansion
- NEOEN FP : Neoen Maintains FY Ebitda EU270M to EU285M, Est. EU282.6M
- NKT DC : NKT Sees FY Adjusted Revenue EU1.1B, Saw EU1B to EU1.1B
- NDX1 GY : Nordex Sees FY Revenue About EU4.4B, Est. EU4.39B
- NAS NO : Norwegian Air 3Q Net Loss NOK1.02B Vs. Profit NOK1.67B Y/y
- NPRO NO : Norwegian Property Offering Prices 50m Shares at NOK11.15/Share
- NPRO NO : Norwegian Property to Offer Up to 50m Shrs NOK11.15/Shr
- OHL SM : Sand Grove to Take 20% Stake in Spain’s OHL: El Confidencial
- ORNBV FH : Orion Invests EU17 Mln in Production Plant in Turku, Finland
- PSPN SW : PSP Swiss 9M Adjusted Ebitda CHF205.6M
- REC BB : Recticel Buys Conzzeta’s FoamPartner in Cash Deal; EV CHF270m
- ROTH FP : Rothschild & Co 9M Revenue EU1.24B
- SGO FP : Saint-Gobain in Exclusive Talks With Mutares to Sell Lapeyre
- SHA GY : Schaeffler Sees FY Revenue In Constant Currency -11.5% to -13%
- SGSN SW : SGS Buys Synlab’s Analytics & Services Unit for About EU550m
- ENR GY : Siemens Energy Swings to Loss as Gas-Power Projects Delayed
- 9984 JP : SoftBank Mulls Moving Vision Fund Unit to Abu Dhabi From UK: FT
- TMV GY : TeamViewer Sees FY Billings EU450M to EU455M, Saw About EU450.0M
- TMV GY : TeamViewer Raises Guidance After Surge in Remote Working
- TKA GY : Thyssenkrupp in Talks for at Least 5 Billion Euros in Steel Aid
- 8TRA GY : Traton CFO Urges ‘Strict Focus’ on Cost Cuts After 3Q Recovery
- TCELL TI : Turkcell Offering Prices at 15.25 Liras Per Share: Statement
- UN01 GY : Uniper Net Income Increases Threefold In First Nine Months
- UN01 GY : Uniper Hedges More Power for Coming Years in Third Quarter
- URW NA : Unibail Shareholders Rejected EU3.5B Capital Increase
- VOE AV : Voestalpine 2Q Ebitda Beats Estimates
- WDI GY : The Man Who Could Explain Wirecard’s $2 Billion Fraud Is Missing
- WLN FP : PayPal, Square Shares Decline With Fintech Stock Rotation
- WLN FP : Worldline Has 93.9% of Ingenico Following Tender Offer

(TWT) Elon Musk: @SamTalksTesla @Tesla Tesla makes the RNA Bioreactor that can make vaccines / cures. CureVac has version 2 in use.


Tesla filed joint patent with CureVac on possibly revolutionary ‘bioreactor for RNA’ (From june 2020)

A patent application shows that Tesla has been working with CureVac on a possibly revolutionary “bioreactor for RNA” for over a year.

Tesla CEO Elon Musk announced yesterday that the automaker has become the manufacturing partner for biotech firm CureVac who is working on a COVID-19 vaccine based on their RNA technology.
The CEO announced that Tesla would be “building RNA micro-factories for CureVac.”
It took many by surprise since it seems like Tesla is making a move in the biotech world, but we now learn that it has been in the works for a long time — even pre-COVID-19.
A tipster sent Electrek a patent application that Tesla jointly filed with CureVac through its Tesla Grohmann division in Germany.
The patent application is called “Bioreactor for RNA in vitro Transcription” and it describes an automated system for RNA manufacturing:
The present invention relates to a bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing. Further, the use of a bioreactor for RNA in vitro transcription as described herein is part of the present invention. The present invention relates to an RNA in vitro transcription reactor designed to be operable in an automated manner under GMP-compliant conditions. In particular, said RNA in vitro transcription reactor allows repetitive use of DNA template for various RNA in vitro transcription reactions. Further, the invention relates to an apparatus for RNA manufacturing comprising (a) a module for template DNA synthesis, (b) a module for transcribing DNA into RNA comprising said RNA in vitro transcription reactor, and, optionally, (c) a module for RNA formulation.
The patent application was filed in June 2019, showing that Tesla has been working with CureVac for over a year.
It describes a problem with current manufacturing processes for RNA molecules being labor extensive and requiring several different equipments.
The Tesla/CureVac solution solves those problems.
They argue that it would be more accurate and easily deployable:
An advantage of an improved bioreactor may be that it may allow for repetitive use of DNA templates in several RNA production processes which reduces the costs as less starting material (that is DNA template) has to be used and DNAse treatment can be omitted or substantially minimized. Moreover, an improved bioreactor may allow for the robust production of RNA with a higher purity profile (no residual DNAse, no residual DNA fragments in final RNA product). Advantages of an automated apparatus for RNA production are that the whole manufacturing process may be more robust and reliable (due to minimizing human error) and that the production of RNA may be accelerated.
Further, an acceleration of RNA manufacturing would be highly advantageous and of major importance for public health, especially in the context of pandemic scenarios. Further advantageous in that context would be the production of the RNA therapeutics in the region of the outbreak which would, however, require a portable RNA production apparatus.
Hence why Musk talked about Tesla making “micro-factories” for CureVac.
Here are some drawings from the patent application:


Here’s the joint Tesla and CureVac patent application in full:

>>> Asian Market update

Asia Market Update: Asia trades mixed despite vaccine news, tech sector lags; Nasdaq FUTs extend losses, Barr to probe alleged voting irregularities; China CPI slows more than expected


General Trend:
- Travel-sensitive and financial firms outperform after the Pfizer/BioNTech vaccine news; tech sector lags
- Consumer Discretionary firms drop in Shanghai, Oct CPI had slowest y/y rise since late 2009
- James Hardie declines by over 5% in Australia amid results/guidance
- Japanese officials declined to comment on size of 3rd extra budget
- RBNZ is due to issue monetary policy statement on Wed (Nov 11th); the central bank is expected to give an update on the development of its policy tools [including Funding for Lending Program]

***Headlines/Economic Data***
Australia/New Zealand
-ASX 200 opened %
- (AU) Australia PM Morrison: Confidence in Domestic economy return; Extends jobkeeper supplement by 3-months
- (AU) Australia ANZ Roy Morgan Weekly Consumer Confidence Index: 103.1 v 99.9 prior (10th consecutive increase)
- (NZ) New Zealand Government 3-Month Financial Statements: Rev NZ$23.7B v NZ$21.6B forecast; Deficit NZ$3.17B v NZ6.5B forecast
- (CN) According to analysts China is waiting for Australia to make the first move to repair relations between the countries, however anti-China sentiment is high in Australia putting the Govt in a difficult position - SCMP

Japan
-Nikkei 225 opened +1.0%
- (JP) Japan PM Suga orders extra budget - Japan press
- (JP) Japan Sept Current Account: ¥1.66T v ¥2.025Te; Adj Current Account: ¥1.35T v ¥1.794Te
- (JP) Japan Econ Min Nishimura: Confirms PM Suga has instructed completion of fresh economic package, nothing has been decided on size yet
- (JP) Japan Fin Min Aso: Japan economic decline was smaller, so rebound will be smaller; many industries are seeing demand recover, including autos
- (JP) Japan MoF sells ¥898.7B v ¥900B indicated in 0.6% 30-year JGBs, avg yield 0.6430% v 0.6380% prior, bid to cover 3.76x v 3.51x prior
-(JP) Japan Oct Eco Watchers Current Survey: 54.5 v 50.5e (Highest level since Jan 2014); Outlook Survey: 49.1 v 49.8e

Korea
-Kospi opened +0.3%
- (KR) South Korea GDP expected to be +3% in 2021 v contraction in 2020 - Korean press
- (KR) South Korea COVID cases in triple digits for 3rd consecutive day, authorities considering implementing stronger social distancing rules

China/Hong Kong
-Hang Seng opened +1.8%; Shanghai Composite opened +0.4%
- (CN) CHINA OCT CPI M/M: -0.3% V +0.2% PRIOR; Y/Y: 0.5% V 0.8%E (slowest y/y pace since Oct 2009); PPI Y/Y: 0.0% v -2.0%e; Pork prices -2.8% y/y (1st decline in 20-months)
- (CN) China PBOC sets Yuan reference rate: 6.5897 v 6.6123 prior
- (HK) Hong Kong Chief Exec Lam: No room to further relax social distancing rules, to extend social distancing rules for 1 week
- 2196.HK Trades limit up after the Pfizer/BionTech vaccine news

North America
- (US) Fed's Kaplan (FOMC dissenter): US economy is in the midst of a rebound out of deep contraction; risk is that a resurgence of COVID could overhelm hospitals and lead to lockdowns
- (US) Fed biannual Financial Stability Report: In the near term, risks associated with the course of COVID-19 and its effects on the U.S. and global economies remain high
- (US) Fed's Quarles (hawk, voter): Fed remains committed to using full range of tools to support economy as long as needed - prepared Congressional testimony
- LLY US FDA authorizes emergency use authorization for Bamlanivimab, an monoclonal antibody drug for COVID
- HDS Lowes comments on rumors: not in talks with Company and has no plans for a transaction with the company
- (US) Joe Biden Transition Team Spokesman: Legal action is a possibility if the GSA does not recognize Biden win in the US Election

Europe
- (UK) House of Lords votes against UK govt on proposed law that would grant ministers the power to override the EU exit treaty - press

***Levels as of 12:15ET***
- Hang Seng +0.8%; Shanghai Composite -0.1%; Kospi 0.0%; Nikkei225 +0.5%; ASX 200 +0.7%
- Equity Futures: S&P500 -0.6%; Nasdaq100 -0.6%, Dax -0.5%; FTSE100 -1.1%
- EUR 1.1840-1.1806; JPY 105.38-104.82; AUD 0.7289-0.7267; NZD 0.6841-0.6809
- Commodity Futures: Gold +1.4% at $1,879/oz; Crude Oil -1.3% at $39.77/brl; Copper +0.1% at $3.14/lb

>>> After Hours Summary: BYND -22.1%, NBIX -13.4%, RAMP -11.4% down on earnings;

After Hours Summary: BYND -22.1%, NBIX -13.4%, RAMP -11.4% down on earnings; XPER +25.7% jumps as it settles litigation with Comcast; ARNA -18% falls on clinical data

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: XPER +25.7% (also announces license agreement with Comcast which ends all litigation between the cos), FLGT +15.3%, SCOR +8.9%, ZI +7%, WES +6.7%, SPT +5%, RNG +4.9% (also also announces expanded partnership with BT), ZIXI +3.7% (also acquires privately-held CloudAlly), TLRY +3.5%, NGL +3.3%, STAY +2.9%, APPF +2.8%, NKLA +2%, INO +1.2%, HAIN +0.9%, DHT +0.8%, OSH +0.7%, SWAV +0.6%, WPM +0.2% (also increases dividend), MWA +0.1%, TCO +0.1%

Companies trading higher in after hours in reaction to news: HDS +15.4% (hearing LOW may be in talks to acquire HDS), AFMD +8.6% (announces licensing and strategic collaboration agreement with Roivant Sciences), SFT +5.8% (launches car marketplace in Texas), VNOM +5.7% (announces $100 mln share buyback plan), NLS +4.3% (files for $100 mln mixed securities shelf offering), LOW +4.1% (hearing LOW may be in talks to acquire HDS), ADBE +1.8% (confirms acquisition of Workfront for $1.5 bln), ACTG +1.7% (stock offerings), NVDA +1.6% (NVIDIA DRIVE to come included in entire lineup of Hyundai, Kia, and Genesis models starting in 2022), BA +1.6% (awarded $660 mln Air Force contract), SSTI +1.2% (to acquire Leeds), LMT +1% (awarded $260 mln Air Force contract; also LUV in talks to acquire as many as 30 737 Max jets that have lost their original buyers, according to Bloomberg), MRK +0.9% (to discontinue KEYNOTE-598 study of KEYTRUDA for futility on recommendation of independent Data Monitoring Committee; also initiates VERSATILE-002 Phase 2 trial), MU +0.4% (begins volume shipments of 176-layer 3D NAND flash memory), ESI +0.1% (initiates dividend), AUPH +0.1% (presents data from integrated analysis of AURA-LV and AURORA pivotal trials)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: BYND -22.1% (saw deterioration of its foodservice business as COVID-19 stay-at-home measures set in), ARNA -18%, NBIX -13.4%, RAMP -11.4%, SPG -8%, REAL -6.5%, IFF -4.8%, NVAX -4.8% (also names new CFO), ZGNX -4.8%, GSKY -2.3%, RPAY -2.2%, OXY -2%, AMBC -1.7%, IHRT -1%, ELY -0.9%, OR -0.5%, MBI -0.3%, AL -0.2%, NCLH -0.2%

Companies trading lower in after hours in reaction to news: ARNA -18% (announces primary endpoint not met in top line results from Phase 2b ADVISE trial; also reports earnings), TXMD -13.2% (stock offering), RVNC -7.6% (says Phase 2 trial for plantar fasciitis; primary efficacy endpoint not met), FSR -4.5% (stock offerings), AVEO -2.8% (files for $300 mln mixed securities shelf offering), FBIO -1.3% (stock offering), SIEN -1.1% (names new CEO, also reports earnings), FITB -0.6% (names new CFO), CDAY -0.1% (CNNE announces sale of 2,139,227 shares of CDAY), INSP -0.1% (announces full integration of Inspire Therapy into German DRG reimbursement system), GVA -0.1% (provides business update), FCPT -0.1% (increases dividend)

FT : World’s largest coal producer warns of bankruptcy risk

World’s largest coal producer warns of bankruptcy risk
Peabody Energy faces end-of-year deadline for negotiations with banks and bondholders

Peabody Energy, the world’s largest private sector coal producer, said there was a risk it could go bankrupt for the second time in five years, as it raced to renegotiate debts in the wake of tumbling demand for the fossil fuel. 

The New York-listed miner is at the centre of upheaval in energy markets as natural gas and renewables replace coal on the North American power grid. The economic fallout of coronavirus has also sapped demand for coal used in steelmaking, an important market for Peabody’s Australian operations. 

St Louis-based Peabody shed $5.2bn in debt while in bankruptcy court in 2016-17, leaving hedge fund Elliott Management, a former debt holder, as its largest shareholder. 

Yet the company is again struggling to meet its debt obligations, according to filings. 

Peabody reported a net loss of $67.2m on Monday as coal sales volumes dropped by 23 per cent in the third quarter to 34.7m short tons. “2020 has been a year unlike any other,” Glenn Kellow, chief executive, told analysts on a conference call. 

In Australia, an insurance company sued Peabody to demand more collateral held against surety bonds, which are a form of guarantee to fund the costs of cleaning up shuttered mines.

Earlier this month the company agreed with the insurer and the writers of other surety bonds to resolve about $800m in collateral requests. 

However, the deal only stands if the company is able to get relief on debt covenants from its banks and to extend the maturity of its 2022 corporate bond with investors by the end of December. 

“They have been unable to reach an agreement with bondholders and their revolver banks,” said a trader at one of the fund managers that holds the 2022 bonds. “It’s really just about whether there is a way to get back to the table. We’ll see.”

The 2022 bond edged lower on Monday to a new low of just above 40 cents on the dollar, having traded close to 100 cents on the dollar in February, before a sell-off prompted by the pandemic. 

Peabody is the fifth-biggest coal producer in Australia. It has five mines producing coking coal, a key ingredient in steel making, and three that churn out thermal coal, which is burnt in power stations to produce electricity.

It is also a leading producer in the US where its coal properties include North Antelope Rochelle, the world’s largest coal mine. A cost-saving joint venture proposed with Arch Resources was blocked by a US judge in September.

Peabody said it was “probable” that its fourth-quarter results would push the company below a required minimum net gearing ratio under its credit agreement with banks. The company reclassified all of its $1.6bn in debt as current on its balance sheet. 

“The combined risks associated with our recent financial results, market conditions, additional collateral demands and potential credit agreement non-compliance raise substantial doubt about . . . our ability to continue as a going concern,” Peabody said.

The company’s shares fell 7.7 per cent on Monday to a new post-bankruptcy low of $1.08.